These receptors compete with the costimulatory receptor DNAX accessory molecule 1 (DNAM1, or CD226) for binding to PVR and function over time to suppress T and NK cell functionality in the tumor microenvironment (TME) (10, 11). Here, PVR is linked to neoplasm.